COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,845 Articles (22,553 medRxiv, 8,292 bioRxiv)

Most recent first Previous |  Page 2996: Articles 29951-29960  | Next

Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins using High-Resolution Mass Spectrometry
Zhang, Y., Zhao, W., Mao, Y., Wang, S., Zhong, Y., Su, T., Gong, M., Lu, X., Cheng, J., Yang, H.
10.1101/2020.03.28.013276 — Posted: 2020-03-29
Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study
Miller, A., Reandelar, M. J., Fasciglione, K., Roumenova, V., Li, Y., Otazu, G. H.
10.1101/2020.03.24.20042937 — Posted: 2020-03-28 Discussion: Onsite | Offsite
RNA genome conservation and secondary structure in SARS-CoV-2 and SARS-related viruses
Rangan, R., Zheludev, I. N., Das, R.
10.1101/2020.03.27.012906 — Posted: 2020-03-28 Discussion: Onsite
Re-analysis of SARS-CoV-2 infected host cell proteomics time-course data by impact pathway analysis and network analysis. A potential link with inflammatory response.
Ortea, I., Bock, J.-O.
10.1101/2020.03.26.009605 — Posted: 2020-03-28
The Nucleocapsid Protein of SARS-CoV-2 Abolished Pluripotency in Human Induced Pluripotent Stem Cells
Lin, Z., Gao, Q., Fang, Q., Mai, J., Zhou, L., Lin, X., Qian, Y., Cai, T., Chen, Z., Wang, P., Lin, B.
10.1101/2020.03.26.010694 — Posted: 2020-03-28
Structure-Based Design, Synthesis and Biological Evaluation of Peptidomimetic Aldehydes as a Novel Series of Antiviral Drug Candidates Targeting the SARS-CoV-2 Main Protease
Dai, W., Zhang, B., Jiang, X.-M., Su, H., Li, J., Zhao, Y., Xie, X., Jin, Z., Peng, J., Liu, F., Li, C., Li, Y., Bai, F., Wang, H., Cheng, X., Cen, X., Hu, S., Yang, X., Wang, J., Liu, X., Xiao, G., Jiang, H., Rao, Z., Zhang, L., Xu, Y., Yang, H., Liu, H.
10.1101/2020.03.25.996348 — Posted: 2020-03-28
SARS-CoV-2 proteome microarray for mapping COVID-19 antibody interactions at amino acid resolution
Wang, H., Hou, X., Wu, X., Liang, T., Zhang, X., Wang, D., Teng, F., Dai, J., Duan, H., Guo, S., Li, Y., Yu, X.
10.1101/2020.03.26.994756 — Posted: 2020-03-28 Discussion: Onsite
Structural Basis for Potent Neutralization of Betacoronaviruses by Single-domain Camelid Antibodies
Wrapp, D., De Vlieger, D., Corbett, K. S., Torres, G. M., Van Breedam, W., Roose, K., van Schie, L., VIB-CMB COVID-19 Response Team, , Hoffmann, M., Pöhlmann, S., Graham, B. S., Callewaert, N., Schepens, B., Saelens, X., McLellan, J. S.
10.1101/2020.03.26.010165 — Posted: 2020-03-28 Discussion: Offsite
Site-specific analysis of the SARS-CoV-2 glycan shield
Watanabe, Y., Allen, J. D., Wrapp, D., McLellan, J. S., Crispin, M.
10.1101/2020.03.26.010322 — Posted: 2020-03-28 Discussion: Onsite
SARS-CoV-2 and ORF3a: Non-Synonymous Mutations and Polyproline Regions
Issa, E., Merhi, G., Panossian, B., Salloum, T., Tokajian, S. T.
10.1101/2020.03.27.012013 — Posted: 2020-03-28

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).